Delivery Order SPE2DB22D9207-SPE2DB24FH5DY

Award Date 8/5/24
Potential Completion Date 8/6/24
Potential Value $8.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,015.65 firm fixed-price delivery order is for the supply of XTANDI 40 MG CAPSULE 120S and does not have a set-aside designation. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 firm fixed-price delivery order is for the supply of XTANDI 40 MG CAPSULES 120S, with a completion date of September 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $25,868.10, is a firm fixed-price delivery order for the supply of XTANDI 40 MG CAPSULE 120S. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, valued at up to $499,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,934.05 firm fixed-price delivery order is for the supply of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,311.35 firm fixed-price delivery order is for the supply of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product, to support the medical needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 firm fixed-price delivery order is for the supply of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. The contract has an ultimate completion date of December 17, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,622.72, is for the delivery of XTANDI 40 MG CAPSULE 120S to the DLA. This is a firm fixed-price delivery order contract with an ultimate completion date of April 22, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 firm fixed-price delivery order is for the supply of 4,567,887,571 units of the pharmaceutical product XTANDI 40 MG CAPSULE 120S. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,934.05 firm fixed-price delivery order is for the supply of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product, with an ultimate completion date of September 4, 2024. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 delivery order is for the supply of 120 units of the prescription drug XTANDI 40 MG CAPSULE. The contract has a firm fixed price and a completion date of May 29, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB24FH5DY
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 firm fixed-price delivery order contract is for the supply of XTANDI 40 MG CAPSULE 120S, a prescription medication. The award is not associated with a set-aside program.

DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. This IDC, which runs through December 31, 2025, complements the company's separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to Department of Defense (DoD) sites, solidifying DMS Pharmaceutical Group's position as a crucial supplier in the federal pharmaceutical supply chain.

Generated 11/4/24, 9:14 AM